摘要
类风湿关节炎是以滑膜炎、慢性系统性炎症反应及自身抗体分泌为特点的自身免疫性疾病。已有研究结果表明,过量表达的IL-6在类风湿关节炎起病与进展过程中发挥着重要作用。Tolicizumab是第1个人源性的IL-6受体抗体,通过特异性识别结合IL-6受体而阻断IL-6生物学活性,发挥抑制类风湿关节炎炎症反应的作用。大量临床试验证据表明,tocilizumab不仅能明显缓解类风湿关节炎的临床症状,而且能防止关节继续遭受破坏。
Rheumatoid arthritis(RA) is characterized by persistent synovitis,systemic chronic inflammation,and autoantibodies secretion.Over-expression of IL-6 has been shown to play an important role in RA.As the first humanized anti-human IL-6 receptor antibody,tolicizumab can be one of the perfect antirheumatic drugs,which can block IL-6 biological actions by binding IL-6 receptor through specific recognition.A large number of clinical studies illustrate that tocilizumab not only shows effects on improving symptoms of RA but also on preventing joint destruction of RA.
出处
《国际病理科学与临床杂志》
CAS
2011年第4期350-356,共7页
Journal of International Pathology and Clinical Medicine
基金
深圳市科技计划项目(201002067)~~